1
|
Engle SM, Chang CY, Ulrich BJ, Satterwhite A, Hayes T, Robling K, Sissons SE, Schmitz J, Tepper RS, Kaplan MH, Sims JT. Predictive biomarker modeling of pediatric atopic dermatitis severity based on longitudinal serum collection. Clin Exp Immunol 2021; 207:uxab009. [PMID: 35020861 PMCID: PMC9113166 DOI: 10.1093/cei/uxab009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 10/08/2021] [Accepted: 11/09/2021] [Indexed: 11/25/2022] Open
Abstract
The pathogenesis of atopic dermatitis (AD) results from complex interactions between environmental factors, barrier defects, and immune dysregulation resulting in systemic inflammation. Therefore, we sought to characterize circulating inflammatory profiles in pediatric AD patients and identify potential signaling nodes which drive disease heterogeneity and progression. We analyzed a sample set of 87 infants that were at high risk for atopic disease based on atopic dermatitis diagnoses. Clinical parameters, serum, and peripheral blood mononuclear cells (PBMCs) were collected upon entry, and at one and four years later. Within patient serum, 126 unique analytes were measured using a combination of multiplex platforms and ultrasensitive immunoassays. We assessed the correlation of inflammatory analytes with AD severity (SCORAD). Key biomarkers, such as IL-13 (rmcorr=0.47) and TARC/CCL17 (rmcorr=0.37), among other inflammatory signals, significantly correlated with SCORAD across all timepoints in the study. Flow cytometry and pathway analysis of these analytes implies that CD4 T cell involvement in type 2 immune responses were enhanced at the earliest time point (year 1) relative to the end of study collection (year 5). Importantly, forward selection modeling identified 18 analytes in infant serum at study entry which could be used to predict change in SCORAD four years later. We have identified a pediatric AD biomarker signature linked to disease severity which will have predictive value in determining AD persistence in youth and provide utility in defining core systemic inflammatory signals linked to pathogenesis of atopic disease.
Collapse
Affiliation(s)
| | | | - Benjamin J Ulrich
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
- Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
| | | | - Tristan Hayes
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
- Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Kim Robling
- Eli Lilly and Company, Indianapolis, IN, USA
| | | | | | - Robert S Tepper
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Mark H Kaplan
- Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
- Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
| | | |
Collapse
|
2
|
Suárez-Pedroso M, Sordo-Puga Y, Sosa-Teste I, Rodriguez-Molto MP, Naranjo-Valdés P, Sardina-González T, Santana-Rodríguez E, Montero-Espinosa C, Frías-Laporeaux MT, Fuentes-Rodríguez Y, Pérez-Pérez D, Oliva-Cárdenas A, Pereda CL, González-Fernández N, Bover-Fuentes E, Vargas-Hernández M, Duarte CA, Estrada-García MP. Novel chimeric E2CD154 subunit vaccine is safe and confers long lasting protection against classical swine fever virus. Vet Immunol Immunopathol 2021; 234:110222. [PMID: 33690056 DOI: 10.1016/j.vetimm.2021.110222] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 02/19/2021] [Accepted: 03/02/2021] [Indexed: 10/22/2022]
Abstract
E2CD154 is a vaccine candidate against classical swine fever (CSF) based on a chimeric protein composed of the E2 glycoprotein fused to porcine CD154 antigen, and formulated in the oil adjuvant Montanide™ ISA 50 V2. This vaccine confers early protection in pigs and prevents vertical transmission in pregnant sows. The objectives of this study were to assess the safety of this immunogen in piglets, to compare several doses of antigen in the formulation, and to study the duration of the immunity provided by this vaccine for up to 9 months. Three trials were conducted by immunizing pigs with a two-dose regime of the vaccine. Challenge experiments were carried out with the highly pathogenic Margarita strain. No local or systemic adverse effects were documented, and neither macroscopic nor microscopic pathological findings were observed in the vaccinated animals. The three antigen doses explored were safe and induced CSF protective neutralizing antibodies. The dose of 50 μg was selected for further development because it provided the best clinical and virological protection. Finally, this protective immunity was sustained for at least 9 months. This study demonstrates that E2CD154 vaccine is safe; defines a vaccine dose of 50 μg antigen, and evidences the capacity of this vaccine to confer long term protection from CSFV infection for up to 9 months post- vaccination. These findings complement previous data on the evaluation of this vaccine candidate, and suggest that E2CD154 is a promising alternative to modified live vaccines in CSF endemic areas.
Collapse
Affiliation(s)
- Marisela Suárez-Pedroso
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba.
| | - Yusmel Sordo-Puga
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Iliana Sosa-Teste
- Centro para la Producción de Animales de Laboratorio (CENPALAB), Centro de Toxicología Experimental (CETEX), Cuba
| | | | | | - Talía Sardina-González
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Elaine Santana-Rodríguez
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Carlos Montero-Espinosa
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | | | - Yohandy Fuentes-Rodríguez
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Danny Pérez-Pérez
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Ayme Oliva-Cárdenas
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Carmen Laura Pereda
- Centro Nacional de Sanidad Agropecuaria (CENSA), Apdo 10, San José de Las Lajas, Havana, Cuba
| | - Nemecio González-Fernández
- Departamento de Desarrollo de Procesos, Centro de Ingeniería Genética y Biotecnología (CIGB), Camagüey, Cuba
| | - Eddy Bover-Fuentes
- Departamento de Desarrollo de Procesos, Centro de Ingeniería Genética y Biotecnología (CIGB), Camagüey, Cuba
| | - Milagros Vargas-Hernández
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Carlos A Duarte
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| | - Mario Pablo Estrada-García
- Departamento de Biotecnología Animal, Centro de Ingeniería Genética y Biotecnología (CIGB), Havana, Cuba
| |
Collapse
|
3
|
Zhang Y, Wang N, Ding M, Yang Y, Wang Z, Huang L, Zhu W, Mellor AL, Hou X, Zhou C, Yan R, Wang W, Wu S. CD40 Accelerates the Antigen-Specific Stem-Like Memory CD8 + T Cells Formation and Human Papilloma Virus (HPV)-Positive Tumor Eradication. Front Immunol 2020; 11:1012. [PMID: 32536922 PMCID: PMC7267052 DOI: 10.3389/fimmu.2020.01012] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 04/28/2020] [Indexed: 01/03/2023] Open
Abstract
Antigen-specific stem-like memory CD8+ T cells (Tscm) have a series of stem cell characteristics, including long-term survival, self-renewal, anti-apoptosis and persistent differentiation into cytotoxic T cells. The effective induction of tumor-specific CD8+ Tscm could persistently eradicate tumor in pro-tumor hostile microenvironment. This study was to investigate the role of CD40 in HPV16-specific CD8+ Tscm induction and its anti-tumor function. We found that CD40 activation accelerated vaccine-induced HPV16 E7-specific CD8+ Tscm formation. Comparing to other HPV-specific CD8+ T cells, CD8+ Tscm were found to be stronger and long-term anti-tumor function, in vivo and in vitro, even in the adoptive cellular transferring model. Furthermore, high frequencies of Tscm might prevent the HPV infection to move on to the development of cancer. And the CD40 effect on Tscm involved Wnt/β-catenin activation. Our study suggest that CD40 activation supports the generation of tumor-specific CD8+ Tscm, thus providing new insight into cancer immunotherapy.
Collapse
Affiliation(s)
- Yanmei Zhang
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, China
| | - Nisha Wang
- Guangdong Provincial Key Laboratory of Single Cell Technology and Application, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
| | - Meilin Ding
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, China
| | - Yang Yang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.,Department of Obstetrics and Gynecology, The Six Affiliated Hospital of Guangzhou Medical University, Qingyuan, China
| | - Zhimin Wang
- Center for Gene and Cellular Immunotherapy, National Center for the International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Lei Huang
- Faculty of Medical Sciences, Framlington Place, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, United Kingdom
| | - Wei Zhu
- Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Andrew L Mellor
- Faculty of Medical Sciences, Framlington Place, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne, United Kingdom
| | - Xiaorui Hou
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, China
| | - Chenfei Zhou
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Ruiming Yan
- Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Wei Wang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Sha Wu
- Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, China
| |
Collapse
|
4
|
Wang Q, Yang M, Zhang Y, Zhong L, Zheng X. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer. Curr Gene Ther 2020; 19:54-65. [PMID: 30848201 DOI: 10.2174/1566523219666190307094713] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 02/17/2019] [Accepted: 02/26/2019] [Indexed: 01/04/2023]
Abstract
BACKGROUND Both Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) suicide gene therapy and exogenous CD40 ligand (CD40L)-CD40 interaction in cancer via conditionally replicating adenovirus can selectively kill tumors without damaging normal tissues. OBJECTIVE To further improve the cancer killing effect, we investigated the therapeutic effect of combined cancer gene therapy based on a selective oncolytic adenovirus vector containing Dm-dNK suicide gene and exogenous CD40L on breast carcinoma cells in vitro and in vivo. METHODS A series of conditionally replicating adenoviruses using adenovirus vector P74 were generated: P74-dNK, P74-CD40L (expressing Dm-dNK or CD40L respectively), and P74-dNK-CD40L (expressing combined Dm-dNK and CD40L). Breast cancer cell lines (MDA-MB-231, MCF-7) and non-tumor cell line (MRC5) were treated with adenovirus and cytotoxicity determined by MTT assay, and apoptosis assessed by flow cytometry after 72h. We also assessed in vivo cell killing efficiency using a mouse xenograft model with MDA-MB-231 cells. RESULTS AND DISCUSSION Co-expression of Dm-dNK and CD40L reduced cell proliferation of MDAMB- 231 or MCF7 cancer cells, and induced more apoptosis in TERT and CD40 positive cancer cells, but not normal MRC5 cells. Significant reduction in tumor volume was also seen in combined treatment arms as compared to any single treatment. CONCLUSION Our data suggest enhanced, selective tumor cell killing using combined gene therapy with conditionally replicating adenovirus containing Dm-dNK suicide gene and exogenous CD40 ligation (CD40L-CD40).
Collapse
Affiliation(s)
- Qiuli Wang
- Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China
| | - Muwen Yang
- Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China
| | - Ye Zhang
- Lab 1, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China
| | - Li Zhong
- Hebei University College of Life Sciences, Baoding, Hebei, China.,College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA, United States
| | - Xinyu Zheng
- Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.,Lab 1, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China
| |
Collapse
|
5
|
Governa V, Brittoli A, Mele V, Pinamonti M, Terracciano L, Muenst S, Iezzi G, Spagnoli GC, Zajac P, Trella E. A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo. Oncoimmunology 2019; 8:e1568162. [PMID: 31069131 PMCID: PMC6492963 DOI: 10.1080/2162402x.2019.1568162] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 11/30/2018] [Accepted: 12/11/2018] [Indexed: 12/14/2022] Open
Abstract
CD40 triggering may result in antitumor effects of potentially high clinical relevance. To gain insights important for patient selection and to identify adequate targeting techniques, we investigated CD40 expression in human cancer tissues and generated a replication-incompetent recombinant vaccinia virus expressing CD40 ligand (rVV40L). Its effects were explored in vitro and in vivo upon direct CD40 targeting on malignant cells or macrophage activation. CD40 expression was analyzed by immunohistochemistry in tumor and stromal cells in a multi-tumor array including 836 specimens from 27 different tumor types. Established tumor cell lines were used to explore the capacity of rVV40L to induce malignant cell apoptosis and modulate functional profiles of polarized macrophages. CD40 expression was detectable in significantly higher numbers of stromal as compared to malignant cells in lung and breast cancers. CD40 ligation following rVV40L infection induced apoptosis in CD40(+) cancer cells, but only in the presence of intact specific signal transduction chain. Importantly, rVV40L infection promoted the induction of TNF-α-dependent antitumor activity of M1-like macrophages directed against CD40(-) targets. CD40-activated M1-like macrophages also displayed enhanced ability to CXCL10-dependently recruit CD8+ T cells and to efficiently present cancer cell intracellular antigens through cross-priming. Moreover, rVV-driven CD40L expression partially “re-educated” M2-like macrophages, as suggested by detectable CXCL10 and IL-12 production. Most importantly, we observed that intra-tumoral injection of rVV40L-infected human macrophages inhibits progression of human CD40(-) tumors in vivo. First evidences of anticancer activity of rVV40L strongly encourage further evaluations.
Collapse
Affiliation(s)
- Valeria Governa
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Alvaro Brittoli
- Department of Pharmaceutical Sciences, University of Piemonte Orientale, Novara, Italy
| | - Valentina Mele
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Maurizio Pinamonti
- Unit of Pathology, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
| | - Luigi Terracciano
- Institute of Pathology, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Simone Muenst
- Institute of Pathology, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Giandomenica Iezzi
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.,Department of Surgery, Ente Ospedaliero Cantonale and Università della Svizzera Italiana, Lugano, Switzerland
| | - Giulio Cesare Spagnoli
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.,Consiglio Nazionale delle Ricerche, Institute of Translational Pharmacology, Rome, Italy
| | - Paul Zajac
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Emanuele Trella
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| |
Collapse
|
6
|
Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev 2019; 141:92-103. [PMID: 30552917 DOI: 10.1016/j.addr.2018.12.005] [Citation(s) in RCA: 171] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 11/12/2018] [Accepted: 12/03/2018] [Indexed: 12/16/2022]
Abstract
CD40 is a TNF receptor superfamily member expressed on both immune and non-immune cells. Interactions between B cell-expressed CD40 and its binding partner, CD40L, predominantly expressed on activated CD4+ T cells, play a critical role in promoting germinal center formation and the production of class-switched antibodies. Non-hematopoietic cells expressing CD40 can also engage CD40L and trigger a pro-inflammatory response. This article will highlight what is known about the biology of the CD40-CD40L axis in humans and describe the potential contribution of CD40 signaling on both hematopoietic and non-hematopoietic cells to autoimmune disease pathogenesis. Additionally, novel therapeutic approaches to target this pathway, currently being evaluated in clinical trials, are discussed.
Collapse
|
7
|
Muñoz-González S, Sordo Y, Pérez-Simó M, Suarez M, Canturri A, Rodriguez MP, Frías-Lepoureau MT, Domingo M, Estrada MP, Ganges L. Corrigendum to "Efficacy of E2 glycoprotein fused to porcine CD154 as a novel chimeric subunit vaccine to prevent classical swine fever virus vertical transmission in pregnant sows". Vet Microbiol 2017; 213:143-149. [PMID: 29126749 DOI: 10.1016/j.vetmic.2017.10.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Here we evaluated the effect of double vaccination with a novel subunit marker vaccine candidate based in the CSFV E2 glycoprotein fused to the porcine CD154 to prevent CSFV vertical transmission. A lentivirus-based gene delivery system was used to obtain a stable recombinant HEK 293 cell line for the expression of E2 fused to porcine CD154 molecule. Six pregnant sows were distributed in two groups and at 64days of gestation animals numbered 1-4 (group 1) were vaccinated via intramuscular inoculation with 50μg of E2-CD154 subunit vaccine. Animals from group 2 (numbered 5 and 6, control animals) were injected with PBS. Seventeen days later sows from group 1 were boosted with the same vaccine dose. Twenty-seven days after the first immunization, the sows were challenged with a virulent CSFV Margarita strain and clinical signs were registered. Samples were collected during the experiment and at necropsy to evaluate immune response and virological protection. Between 14 and 18days after challenge, the sows were euthanized, the foetuses were obtained and samples of sera and tissues were collected. E2-CD154 vaccinated animals remained clinically healthy until the end of the study; also, no adverse reaction was shown after vaccination. An effective boost effect in the neutralizing antibody response after the second immunization and viral challenge was observed and supports the virological protection detected in these animals after vaccination. Protection against CSFV vertical transmission was found in the 100% of serums samples from foetus of vaccinated sows. Only two out of 208 samples (0.96%) were positive with Ct value about 36 corresponding to one tonsil and one thymus, which may be non-infective viral particles. Besides, its DIVA potential and protection from vertical transmission, the novel CSFV E2 bound to CD154 subunit vaccine, is a promising alternative to the live-attenuated vaccine for developing countries.
Collapse
Affiliation(s)
- Sara Muñoz-González
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Yusmel Sordo
- Animal Biotechnology Department, Center for Genetic Engineering and Biotecnology (CIGB), Havana, Cuba
| | - Marta Pérez-Simó
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Marisela Suarez
- Animal Biotechnology Department, Center for Genetic Engineering and Biotecnology (CIGB), Havana, Cuba
| | - Albert Canturri
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Maria Pilar Rodriguez
- Animal Biotechnology Department, Center for Genetic Engineering and Biotecnology (CIGB), Havana, Cuba
| | | | - Mariano Domingo
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Mario Pablo Estrada
- Animal Biotechnology Department, Center for Genetic Engineering and Biotecnology (CIGB), Havana, Cuba.
| | - Llilianne Ganges
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
| |
Collapse
|
8
|
Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice. Vaccine 2017; 35:5794-5798. [PMID: 28939158 DOI: 10.1016/j.vaccine.2017.09.037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 08/07/2017] [Accepted: 09/12/2017] [Indexed: 11/24/2022]
Abstract
We previously developed and characterized an adenoviral-based prostate cancer vaccine for simultaneous targeting of prostate-specific antigen (PSA) and prostate stem cell antigen (PSCA). We also demonstrated that immunization of mice with the bivalent vaccine (Ad5-PSA+PSCA) inhibited the growth of established prostate tumors. However, there are multiple challenges hindering the success of immunological therapies in the clinic. One of the prime concerns has been to overcome the immunological tolerance and maintenance of long-term effector T cells. In this study, we further characterized the use of the bivalent vaccine (Ad5-PSA+PSCA) in a transgenic mouse model expressing human PSA in the mouse prostate. We demonstrated the expression of PSA analyzed at the mRNA level (by RT-PCR) and protein level (by immunohistochemistry) in the prostate lobes harvested from the PSA-transgenic (PSA-Tg) mice. We established that the administration of the bivalent vaccine in surgifoam to the PSA-Tg mice induces strong PSA-specific effector CD8+ T cells as measured by IFN-γ secretion and in vitro cytotoxic T-cell assay. Furthermore, the use of surgifoam with Ad5-PSA+PSCA vaccine allows multiple boosting vaccinations with a significant increase in antigen-specific CD8+ T cells. These observations suggest that the formulation of the bivalent prostate cancer vaccine (Ad5-PSA+PSCA) with surgifoam bypasses the neutralizing antibody response, thus allowing multiple boosting. This formulation is also helpful for inducing an antigen-specific immune response in the presence of self-antigen, and maintains long-term effector CD8+ T cells.
Collapse
|
9
|
Muñoz-González S, Sordo Y, Pérez-Simó M, Suárez M, Canturri A, Rodriguez MP, Frías-Lepoureau MT, Domingo M, Estrada MP, Ganges L. Efficacy of E2 glycoprotein fused to porcine CD154 as a novel chimeric subunit vaccine to prevent classical swine fever virus vertical transmission in pregnant sows. Vet Microbiol 2017. [PMID: 28622852 DOI: 10.1016/j.vetmic.2017.05.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Here we evaluated the effect of double vaccination with a novel subunit marker vaccine candidate based in the CSFV E2 glycoprotein fused to the porcine CD154 to prevent CSFV vertical transmission. A lentivirus-based gene delivery system was used to obtain a stable recombinant HEK 293 cell line for the expression of E2 fused to porcine CD154 molecule. Six pregnant sows were distributed in two groups and at 64days of gestation animals numbered 1-4 (group 1) were vaccinated via intramuscular inoculation with 50μg of E2-CD154 subunit vaccine. Animals from group 2 (numbered 5 and 6, control animals) were injected with PBS. Seventeen days later sows from group 1 were boosted with the same vaccine dose. Twenty-seven days after the first immunization, the sows were challenged with a virulent CSFV Margarita strain and clinical signs were registered. Samples were collected during the experiment and at necropsy to evaluate immune response and virological protection. Between 14 and 18days after challenge, the sows were euthanized, the foetuses were obtained and samples of sera and tissues were collected. E2-CD154 vaccinated animals remained clinically healthy until the end of the study; also, no adverse reaction was shown after vaccination. An effective boost effect in the neutralizing antibody response after the second immunization and viral challenge was observed and support the virological protection detected in these animals after vaccination. Protection against CSFV vertical transmission was found in the 100% of serums samples from foetus of vaccinated sows. Only two out of 208 samples (0.96%) were positive with Ct value about 36 corresponding to one tonsil and one thymus, which may be non-infective viral particles. Besides, its DIVA potential and protection from vertical transmission, the novel CSFV E2 bound to CD154 subunit vaccine, is a promising alternative to the live-attenuated vaccine for developing countries.
Collapse
Affiliation(s)
- Sara Muñoz-González
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Yusmel Sordo
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Marta Pérez-Simó
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Marisela Suárez
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Albert Canturri
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Maria Pilar Rodriguez
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | | | - Mariano Domingo
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain
| | - Mario Pablo Estrada
- Animal Biotechnology Department, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
| | - Llilianne Ganges
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
| |
Collapse
|
10
|
Governa V, Trella E, Mele V, Tornillo L, Amicarella F, Cremonesi E, Muraro MG, Xu H, Droeser R, Däster SR, Bolli M, Rosso R, Oertli D, Eppenberger-Castori S, Terracciano LM, Iezzi G, Spagnoli GC. The Interplay Between Neutrophils and CD8 + T Cells Improves Survival in Human Colorectal Cancer. Clin Cancer Res 2017; 23:3847-3858. [PMID: 28108544 DOI: 10.1158/1078-0432.ccr-16-2047] [Citation(s) in RCA: 145] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 12/14/2016] [Accepted: 12/21/2016] [Indexed: 01/11/2023]
Abstract
Purpose: Tumor infiltration by different T lymphocyte subsets is known to be associated with favorable prognosis in colorectal cancer. Still debated is the role of innate immune system. We investigated clinical relevance, phenotypes, and functional features of colorectal cancer-infiltrating CD66b+ neutrophils and their crosstalk with CD8+ T cells.Experimental Design: CD66b+ and CD8+ cell infiltration was analyzed by IHC on a tissue microarray including >650 evaluable colorectal cancer samples. Phenotypic profiles of tissue-infiltrating and peripheral blood CD66b+ cells were evaluated by flow cytometry. CD66b+/CD8+ cells crosstalk was investigated by in vitro experiments.Results: CD66b+ cell infiltration in colorectal cancer is significantly associated with increased survival. Interestingly, neutrophils frequently colocalize with CD8+ T cells in colorectal cancer. Functional studies indicate that although neutrophils are devoid of direct antitumor potential, coculture with peripheral blood or tumor-associated neutrophils (TAN) enhances CD8+ T-cell activation, proliferation, and cytokine release induced by suboptimal concentrations of anti-CD3 mAb. Moreover, under optimal activation conditions, CD8+ cell stimulation in the presence of CD66b+ cells results in increasing numbers of cells expressing CD45RO/CD62L "central memory" phenotype. Importantly, combined tumor infiltration by CD66b+ and CD8+ T lymphocytes is associated with significantly better prognosis, as compared with CD8+ T-cell infiltration alone.Conclusions: Neutrophils enhance the responsiveness of CD8+ T cells to T-cell receptor triggering. Accordingly, infiltration by neutrophils enhances the prognostic significance of colorectal cancer infiltration by CD8+ T cells, suggesting that they might effectively promote antitumor immunity. Clin Cancer Res; 23(14); 3847-58. ©2017 AACR.
Collapse
Affiliation(s)
- Valeria Governa
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
- Molecular Pathology Division, Institute of Pathology, Basel University Hospital and University of Basel, Switzerland
| | - Emanuele Trella
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Valentina Mele
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Luigi Tornillo
- Molecular Pathology Division, Institute of Pathology, Basel University Hospital and University of Basel, Switzerland
| | - Francesca Amicarella
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Eleonora Cremonesi
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Manuele Giuseppe Muraro
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Hui Xu
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Raoul Droeser
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
- Department of General Surgery, Basel University Hospital and University of Basel, Switzerland
| | - Silvio R Däster
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
- Department of General Surgery, Basel University Hospital and University of Basel, Switzerland
| | - Martin Bolli
- Department of Visceral Surgery, St. Claraspital, Basel, Switzerland
| | - Raffaele Rosso
- Department of Visceral Surgery, Ospedale Civico, Lugano, Switzerland
| | - Daniel Oertli
- Department of General Surgery, Basel University Hospital and University of Basel, Switzerland
| | - Serenella Eppenberger-Castori
- Molecular Pathology Division, Institute of Pathology, Basel University Hospital and University of Basel, Switzerland
| | - Luigi M Terracciano
- Molecular Pathology Division, Institute of Pathology, Basel University Hospital and University of Basel, Switzerland
| | - Giandomenica Iezzi
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland
| | - Giulio C Spagnoli
- Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland.
| |
Collapse
|